There's no discounting the importance of an approval from the Food and Drug Administration when it comes to pharmaceutical investing, particularly when you're dealing with small-cap stocks with few -- if any -- commercialized drugs. While United Therapeutics' (NASDAQ:UTHR) classification falls somewhere between a big-pharma stalwart and feeble clinical-stage, an upcoming FDA approval decision regarding its pulmonary arterial hypertension drug Remodulin is an important development to watch. 

In the following video, health care bureau chief Brenton Flynn and analyst David Williamson discuss the situation in more detail, and how it has repercussions for another small-cap pharma stock.

Brenton Flynn and David Williamson have no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.